WebinarsNew
Deep DiveNew
Explore Business Standard
A group of 25 Democratic-ruled states has moved a US court against President Donald Trump's decision to impose tariffs on 60 economies accounting for 99.4 per cent of American imports. Last month, the US imposed a fresh round of tariffs ranging between 10 per cent and 12.5 per cent on these 60 countries, citing failure on the issue of forced labour, to replace the 10 per cent global levies that expired on July 24. The 25 states moved the US Court of International Trade on Monday against the Trump administration for again implementing tariffs on several countries, contending that it will raise costs for consumers and businesses nationwide. New York Attorney General Letitia James, Governor Kathy Hochul and the coalition of the Democratic states are asking the Court of International Trade to declare these tariffs illegal. "After losing at the Supreme Court, the administration is once again trying to illegally raise taxes on families and businesses with a new round of tariffs," James s
Days after the US Senate cleared a new bill that would authorise President Donald Trump to impose tariffs of up to 100 per cent on India, China and other major buyers of Russian oil and gas, New Delhi on Friday said it was closely monitoring the situation. The bill will now be taken up by the House of Representatives for deliberation. "On energy security, our position has been clarified and very well articulated on several occasions. It is something which is predicated on our national priorities and on securing the energy needs of our 1.4 billion people through diversified sources, which includes the US," External affairs ministry spokesperson Randhir Jaiswal said. He was responding to a question on the US Senate clearing the bill by 86-12 vote. "We remain engaged with relevant stakeholders in the US at various levels on this particular matter," Jaiswal said. The Lindsey O Graham Sanctioning Russia and Iran Act of 2026 would impose primary and secondary sanctions against Russia an
India's pharmaceutical industry should treat the proposed US tariffs on imported generic medicines as a wake-up call to reduce dependence on a single export market, diversify globally and accelerate innovation while ensuring uninterrupted access to affordable medicines, industry leaders and healthcare experts said. US President Donald Trump has announced a phased tariff framework under which imported generic medicines will continue to attract zero tariffs until August 1, 2028, before facing a 100 per cent tariff for one year and a 200 per cent tariff from August 1, 2029. The proposal, aimed at encouraging drug manufacturing in the US, has triggered a debate within India's pharmaceutical sector over its long-term implications. Nikhil K Masurkar, CEO, ENTOD Pharmaceuticals, described the proposed tariffs as an opportunity for long-term strategic transformation, rather than merely a trade challenge. "The finer details of the proposed US tariffs on generic drugs are still unclear, but
The 10 per cent tariff imposed by the US on imports from India will increase the cost of Indian products in the American markets, though the overall impact should be viewed in the proper competitive perspective rather than through the headline tariff alone, according to exporters. The United States has imposed a 10 per cent tariff on goods imported from India and 16 other countries as part of its efforts to combat the use of forced labour in the production of such items. The Federation of Indian Export Organisations (FIEO) has stated that "while the additional 10 per cent Section 301 tariff imposed by the United States on imports from India will increase the landed cost of Indian products, the overall impact should be viewed in the proper competitive perspective rather than through the headline tariff alone". S C Ralhan, President, FIEO, said the fact that India has been placed in the lower 10 per cent tariff category, while several competing exporting nations including China, ...